MetaCap

Jaguar Health (JAGX) vs Kiora Pharmaceuticals (KPRX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Kiora Pharmaceuticals is the larger company by market cap ($3.2 million vs $3.0 million), about 1.1 times the size, while Jaguar Health is growing revenue faster (-1.5% vs -100.0%).

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

JAGX-95.46%KPRX-71.53%
+6%-47%-100%
Oct 7, 20261 yearNov 20, 2026
JAGX-95.26%KPRX-71.65%
+5%-48%-100%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

JAGX versus KPRX key metrics
MetricJAGXKPRX
Share price$0.227$0.7202
Market cap$3.03M$3.19M
1-day change-30.58%-12.28%
YTD return—-63.44%
1-year return—-61.49%
5-year return—-99.87%
EPS (TTM)$-257.15$-2.72
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$11.51M$0
Revenue growth (YoY)-1.52%-100.00%
Net income (latest FY)$-53.58M$-10.84M
Gross margin67.21%—
Operating margin-398.82%—
Net margin-465.42%—
52-week high$981.75$2.91
52-week low$0.22$0.72
Distance from 52-week high-99.98%-75.25%
Analyst consensus—none
Avg. price target upside—+1566.20%
Average volume2.40M35.23K
Shares outstanding13.35M4.42M
Employees4713
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Jaguar Health grew revenue faster in its latest fiscal year (-1.52% vs -100.00%).

About Jaguar Health

JAGX stock →

Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. It operates through two segments, Animal Health and Human Health.

Health Care · Biotechnology: Pharmaceutical Preparations · 47 employees

About Kiora Pharmaceuticals

KPRX stock →

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees

JAGX vs KPRX FAQ

Which is bigger, Jaguar Health or Kiora Pharmaceuticals?

Kiora Pharmaceuticals (KPRX) is larger, with a market capitalization of $3.19M compared with $3.03M for Jaguar Health (JAGX).

Are Jaguar Health and Kiora Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons